ClinConnect ClinConnect Logo
Search / Trial NCT00450957

Lycopene in Healthy Male Participants

Launched by NATIONAL CANCER INSTITUTE (NCI) · Mar 20, 2007

Trial Information

Current as of June 08, 2025

Completed

Keywords

ClinConnect Summary

OBJECTIVES:

I. Compare the toxicity and safety of 2 different doses of oral lycopene in healthy male participants.

II. Compare the pharmacokinetics of 2 different doses of this drug in these participants.

III. Determine the toxicity and pharmacokinetics needed to proceed to a large phase II/III study in men at high risk for prostate cancer.

OUTLINE: This is a randomized, crossover study. Participants are randomized to 1 of 2 treatment arms.

Arm I: Participants receive high-dose oral lycopene once or twice a day for 14 days. After 2 weeks of a lycopene-free period, participants crossove...

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • Healthy volunteers judged to be in good medical condition based on history and physical exam
  • Karnofsky performance status 100%
  • AST and ALT ≤ 75 IU/L
  • Bilirubin ≤ 2.0 mg/dL
  • Creatinine ≤ 1.5 mg/dL
  • Hemoglobin ≥ 13.0 g/dL
  • WBC ≥ 4,000/mm³
  • Platelet count ≥ 150,000/mm³ and ≤ 400,000/mm³
  • Must be within height and weight standards identified by Metropolitan Life scales
  • Nonsmoker (for ≥ 3 months)
  • No history of alcohol abuse
  • No history of gastrointestinal malabsorption or other condition that could affect drug absorption
  • No history of a psychiatric condition
  • No chronic medical condition
  • * No active history of any of the following:
  • Cancer
  • Liver disease
  • Cardiovascular disease
  • Renal disease
  • Diabetes mellitus
  • Other illnesses that, in the opinion of the investigator, could represent a threat for the participants life
  • No allergy to tomato-based products
  • No lycopene in the diet for ≥ 14 days
  • At least 4 weeks since prior and no other concurrent experimental medications
  • No concurrent participation in another experimental study
  • No concurrent use of regular prescription medication or over-the-counter medications
  • No concurrent vitamin, mineral, or herbal supplements

About National Cancer Institute (Nci)

The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.

Locations

Chicago, Illinois, United States

Patients applied

0 patients applied

Trial Officials

Keith Rodvold

Principal Investigator

University of Illinois at Chicago

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials